A new oral therapy for long QT syndrome -: Long-term oral potassium improves repolarization in patients with HERG mutations

被引:94
作者
Etheridge, SP
Compton, SJ
Tristani-Firouzi, M
Mason, JW
机构
[1] Univ Utah, Sch Med, Primary Childrens Med Ctr, Salt Lake City, UT 84113 USA
[2] Univ Utah, Sch Med, Div Pediat Cardiol, Salt Lake City, UT 84113 USA
[3] Alaska Heart Inst, Anchorage, AK USA
[4] Univ Kentucky, Div Cardiol, Lexington, KY 40506 USA
关键词
D O I
10.1016/j.jacc.2003.07.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES We sought to determine whether oral potassium supplementation safely increases serum K+ and results in sustained improvement of repolarization parameters in long QT syndrome type 2 (LQT2) subjects. BACKGROUND Mutations in HERG (LQT2), the gene encoding the rapid delayed rectifier K+ current I-Kr, account for a significant proportion of congenital long QT syndrome (LQTS). The magnitude of I-Kr is paradoxically increased by an increase in extracellular K+. We tested the hypothesis that long-term oral potassium supplementation results in a mild, sustainable increase in serum K+ that improves repolarization abnormalities in subjects with LQT2. METHODS After an initial evaluation consisting of electrocardiography, electrolytes, blood urea nitrogen, and creatinine, escalating doses of potassium chloride (KCl) and spironolactone were administered to eight subjects with six distinct HERG mutations. Medications were continued for four weeks, at which time, the final evaluation was undertaken. Beta-adrenergic blocking therapy was maintained. RESULTS The subjects ranged in age from 11 to 52 years. The average daily KCl and spironolactone dose was 3.3 +/- 1.5 mEq/kg and 3.5 +/- 1.2 mg/kg, respectively, and this regimen resulted in an increase in serum K+ from 4.0 +/- 0.3 to 5.2 +/- 0.3 mEq/l. There were no serious complications associated with therapy. The increase in serum K+ resulted in a decrease in the corrected QT interval from 526 +/- 94 to 423 +/- 36 ms (mean +/- SD; lead V-2). Both QT dispersion and T-wave morphology improved in most subjects. CONCLUSIONS Long-term oral potassium administration increases serum K+ in patients with LQT2. This can be achieved safely and results in improvement in repolarization. Further studies are warranted to determine whether this will reduce the incidence of fife-threatening events in LQTS patients. (C) 2003 by the American College of Cardiology Foundation.
引用
收藏
页码:1777 / 1782
页数:6
相关论文
共 26 条
[1]   The Long QT Syndromes: Genetic basis and clinical implications [J].
Chiang, CE ;
Roden, DM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (01) :1-12
[2]   Genetically defined therapy of inherited long-QT syndrome - Correction of abnormal repolarization by potassium [J].
Compton, SJ ;
Lux, RL ;
Ramsey, MR ;
Strelich, KR ;
Sanguinetti, MC ;
Green, LS ;
Keating, MT ;
Mason, JW .
CIRCULATION, 1996, 94 (05) :1018-1022
[3]  
CORABOEUF E, 1974, J PHARMACOL EXP THER, V191, P128
[4]   Retention in the endoplasmic reticulum as a mechanism of dominant-negative current suppression in human long QT syndrome [J].
Ficker, E ;
Dennis, AT ;
Obejero-Paz, CA ;
Castaldo, P ;
Taglialatela, M ;
Brown, AM .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2000, 32 (12) :2327-2337
[5]   The dominant negative LQT2 mutation A561V reduces wild-type HERG expression [J].
Kagan, A ;
Yu, ZH ;
Fishman, GI ;
McDonald, TV .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (15) :11241-11248
[6]   Molecular and cellular mechanisms of cardiac arrhythmias [J].
Keating, MT ;
Sanguinetti, MC .
CELL, 2001, 104 (04) :569-580
[7]   Defective human ether-a-go-go-related gene trafficking linked to an endoplasmic reticulum retention signal in the C terminus [J].
Kupershmidt, S ;
Yang, T ;
Chanthaphaychith, S ;
Wang, ZQ ;
Towbin, JA ;
Roden, DM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (30) :27442-27448
[8]   ASSESSMENT OF QT DISPERSION IN SYMPTOMATIC PATIENTS WITH CONGENITAL LONG QT SYNDROMES [J].
LINKER, NJ ;
COLONNA, P ;
KEKWICK, CA ;
TILL, J ;
CAMM, AJ ;
WARD, DE .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 69 (06) :634-638
[9]   Management of patients with the hereditary long QT syndrome [J].
Moss, AJ .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 1998, 9 (06) :668-674
[10]   Effectiveness and limitations of β-blocker therapy in congenital long-QT syndrome [J].
Moss, AJ ;
Zareba, W ;
Hall, WJ ;
Schwartz, PJ ;
Crampton, RS ;
Benhorin, J ;
Vincent, GM ;
Locati, EH ;
Priori, SG ;
Napolitano, C ;
Medina, A ;
Zhang, L ;
Robinson, JL ;
Timothy, K ;
Towbin, JA ;
Andrews, ML .
CIRCULATION, 2000, 101 (06) :616-623